An Agenda for Global Fiscal Activism (Jim O'Neill, Project-Syndicate)

https://www.project-syndicate.org/commentary/fiscal-activism-health-education-by-jim-o-neill-2016-11

Building Up the BRICS (Jim O'Neill, Project-Syndicate)

This year marks the 15th anniversary of the “BRICs,” the term I coined to refer to the major emerging economies: Brazil, Russia, India, and China (South Africa was added in 2010). Recently, my brief tenure in the British government came to an end, following the completion of an independent review on antimicrobial resistance (AMR) that I had been chairing. As I ponder what to do next, I can’t help but return to the subject of the anniversary. Have those large and promising emerging economies fulfilled expectations?

https://www.project-syndicate.org/commentary/enduring-importance-of-brics-by-jim-o-neill-2016-10

On Antimicrobial Resistance, It’s Now or Never (Jim O'Neill, Eric Goosby, Project-Syndicate)

https://www.project-syndicate.org/commentary/antimicrobial-resistance-un-general-assembly-by-jim-o-neill-and-eric-goosby-2016-09

Global Cooperation as a Life-and-Death Issue (Jim O'Neill, Project-Syndicate)

The uncertainty generated by the United Kingdom’s recent vote to leave the European Union – which has sent shockwaves through global markets – has been dominating headlines. But, as we prepare to face new political trials, we must not lose sight of the challenges we already face, especially global health challenges like the rise of antimicrobial resistance (AMR), which has no regard for economic performance or political stability.

https://www.project-syndicate.org/commentary/antimicrobial-resistance-global-cooperation-by-jim-o-neill-2016-07

Overcoming Market Obstacles to New Antibiotics (Jim O'Neill, Project-Syndicate)

From the strict perspective of some investors, astute financial management by a company to bolster its share price is a good thing. By this narrow logic, when it comes to the pharmaceutical industry, we should be unconcerned if drug firms’ share prices are boosted not by new discoveries, but by financial maneuvers, such as share buybacks or tax inversion.

https://www.project-syndicate.org/commentary/market-obstacles-to-new-antibiotics-by-jim-o-neill-2016-04

Back to Disease-Fighting Basics (Jim O'Neill, Project-Syndicate)

Combating antimicrobial resistance will require groundbreaking technological solutions. To prevent superbugs from claiming an estimated ten million lives a year by 2050, we will need to invent new types of antimicrobial drugs and develop rapid diagnostic tests to avoid unnecessary treatment and cut our massive overuse of antibiotics.

https://www.project-syndicate.org/commentary/fight-antimicrobial-resistance-through-sanitation-by-jim-o-neill-2016-03

Vaccines Versus Superbugs (Jim O'Neill, Project-Syndicate)

The outbreak of the Zika virus, like Ebola before it, has highlighted the risk that infectious diseases can pose to the health of entire countries – and the importance of vaccines to the fight against fast-moving epidemics. Indeed, efforts are already underway to find ways to inoculate people against both viruses.

http://www.project-syndicate.org/commentary/vaccines-could-slow-antimicrobial-drug-resistance-by-jim-o-neill-2016-02

(Istituto fondamentale - Global) Squashing the Superbugs (Jim O'Neill, Project-Syndicate)

http://www.project-syndicate.org/commentary/political-commitment-fight-antimicrobial-resistance-by-jim-o-neill-2015-06